Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.

Thumbnail Image

Files

Phase 12a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.pdf (481.57 KB)

Embargo End Date

ICR Authors

Tunariu, Nina
 Rata, Mihaela
 Lopez, Juanita

Authors

Kristeleit, R
Evans, J
Molife, LR
Tunariu, N
Shaw, H
Slater, S
Haris, NRM
Brown, NF
Forster, MD
Diamantis, N
Rulach, R
Greystoke, A
Asghar, U
Rata, M
Anderson, S
Bachmann, F
Hannah, A
Kaindl, T
Lane, HA
Larger, PJ
Schmitt-Hoffmann, A
Engelhardt, M
Tzankov, A
Plummer, R
Lopez, J

Document Type

Journal Article

Date

2020-10-27

Date Accepted

2020-07-16

Abstract

BACKGROUND: BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in human cancer models refractory to clinically relevant microtubule-targeting agents. METHODS: This two-part, open-label, phase 1/2a study aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of 2-h infusion of BAL101553 in adults with advanced or recurrent solid tumours. The MTD was determined using a modified accelerated titration design in phase I. Patients received BAL101553 at the MTD and at lower doses in the phase 2a expansion to characterise safety and efficacy and to determine the recommended phase 2 dose (RP2D). RESULTS: Seventy-three patients received BAL101553 at doses of 15-80 mg/m2 (phase 1, n = 24; phase 2a, n = 49). The MTD was 60 mg/m2; DLTs observed at doses ≥60 mg/m2 were reversible Grade 2-3 gait disturbance with Grade 2 peripheral sensory neuropathy. In phase 2a, asymptomatic myocardial injury was observed at doses ≥45 mg/m2. The RP2D for 2-h intravenous infusion was 30 mg/m2. The overall disease control rate was 26.3% in the efficacy population. CONCLUSIONS: The RP2D for 2-h infusion of BAL101553 was well tolerated. Dose-limiting neurological and myocardial side effects were consistent with the agent's vascular-disrupting properties. CLINICAL TRIAL REGISTRATION: EudraCT: 2010-024237-23.

Citation

British Journal of Cancer, 2020, 123 (9), pp. 1360 - 1369

DOI

10.1038/s41416-020-1010-8

URI

https://repository.icr.ac.uk/handle/internal/5804

Rights

http://creativecommons.org/licenses/by/4.0/

Source Title

British Journal of Cancer

Publisher

SPRINGERNATURE

ISSN

0007-0920

eISSN

1532-1827
1532-1827

Collections

Clinical Studies

Research Team

Early Phase Drug Develop

Notes